Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :18946750
Publication Date : //

Current topics and perspectives relating to hormone therapy for prostate cancer.


Prostate cancer is androgen-dependent, and hormone therapy, mainly achieved by androgen deprivation, has been one of the main treatment modalities in the clinical management of prostate cancer patients for more than six decades. In the 1980s, luteinizing hormone-releasing hormone agonists, which reduce testosterone to castration levels, were introduced Also, after the 1980s, nonsteroidal antiandrogens were developed in addition to steroidal antiandrogens. Since then, so-called maximum androgen blockade (MAB)/combined androgen blockade (CAB), which is a combination of surgical or medical castration and oral antiandrogens, has been developed. More recently, novel treatment modalities have been developed, such as intermittent androgen suppression, nonsteroidal antiandrogen monotherapy, and alternative antiandrogen therapy after relapse from initial MAB/CAB, The present article focuses on these treatment modalities to review current topics and perspectives with respect to hormone therapy for prostate cancer.

Authors : Suzuki Hiroyoshi , Kamiya Naoto , Imamoto Takashi , Kawamura Koji , Yano Masashi , Takano Makoto , Utsumi Takanobu , Naya Yukio , Ichikawa Tomohiko ,

Related products :

Catalog number Product name Quantity
EIAAB40264 Homo sapiens,Human,Metalloreductase STEAP2,PCANAP1,Prostate cancer-associated protein 1,Protein upregulated in metastatic prostate cancer,PUMPCn,Six-transmembrane epithelial antigen of prostate 2,SixT
27-424 Altered expression of GBX2, part of the homeobox-containing human family of DNA-binding transcription factors, is associated with therapy failure and death in patients with multiple types of cancer. 0.1 mg
Prostate - PRC481 Prostate cancer tissue array contains 17 cases of pancreatic tumors and 7 cases of normal and reactive prostate tissues. 2mm
PR207b High_density prostate cancer (1_4 grade) and normal prostate tissue array, 70 cases_208 cores
PR721 Prostate cancer normal prostate tissue array with TNM, grade and Gleason scores, 24 cases_72 cores
PR2085b High_density (208 core) prostate adenocarcinoma (I_4 grade) and normal prostate (from autopsy and cancer adjacent) tissue BLOCK
PR208 High_density (70 cases_208 cores), multiple prostate cancer (1_4 grade), normal prostate and placenta tissue array
PR2085a High_density (114 cases_208 cores) prostate adenocarcinoma (I_4 grade) and normal prostate (from autopsy and cancer adjacent) tissue array
orb80727 Human Goserelin protein Goserelin is hormone similar to the one normally released from the hypothalamus gland in the brain (GnRH super-agonist). It is used to treat for prostate and breast cancer.Gose 5 mg
PR481 Prostate cancer tissue array with unmatched normal prostate tissues, 24 cases_48 cores, with grades, stages and Gleason scores
PR721 Prostate cancer normal prostate tissue array with TNM, grade and Gleason scores, 24 cases_72 cores; ihc Anti-Actin confirmed
PR207b High-density prostate cancer (1-4 grade) and normal prostate tissue array, 70 cases_208 cores, replaced by PR208; ihc P504S confirmed
T191 Prostate cancer test tissue array, with normal prostate control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores
PR481 Prostate cancer tissue array with unmatched normal prostate tissues, 24 cases_48 cores, with grades, stages and Gleason scores; ihc Anti-Actin confirmed
PR208 High-density prostate cancer tissue array(1-4 grade), normal prostate and placenta (as control), 70 cases_208 cores, replacing PR207b; ihc P504S confirmed
PR807a Prostate cancer, hyperplasia and normal tissue array, including TNM and pathology grade, 79 cases_80 cores, replacing PR807; ihc Anti-Prostate Specific Antigen (PSA) confirmed
T191 Prostate cancer test tissue array, with normal prostate control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores; ihc Anti-Actin confirmed
PR2085a High-density (114 cases_208 cores) prostate adenocarcinoma (grade 1-4) and normal prostate (from autopsy and cancer adjacent) tissue array, replaced by PR2085b; ihc Anti-Actin confirmed
PR801 Prostate cancer tissue array with unmatched normal prostate tissue, 78 cases_80 cores, replaced by PR803
PR803 Prostate cancer tissue array with unmatched normal prostate tissue, 80 cases_80 cores, replacing PR801
PRF281 Prostate cancer frozen tissue array, with grade and Gleason scores and normal prostate tissue control, 28 cases_28 cores; ihc H&E and Anti-Actin confirmed
1541 Prostate cancer tissue array with adjacent normal prostate tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing PR243
1540 Prostate cancer tissue array with adjacent normal prostate tissue, including TNM, clinical stage and pathology grade, 12 cases_24 cores, replacing PR242
T193 Prostate cancer test tissue array, with normal prostate tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores
PR801 Prostate cancer tissue array with unmatched normal prostate tissue, 78 cases_80 cores, replaced by PR803; ihc Anti-Proliferating Cell Nuclear Antigen antibody confirmed


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur